Human polymer-based cartilage grafts for the regeneration of articular cartilage defects.
The use of autologous chondrocyte implantation (ACI) and its further development combining autologous chondrocytes with bioresorbable matrices may represent a promising new technology for cartilage regeneration in orthopaedic research. Aim of our study was to evaluate the applicability of a resorbable three-dimensional polymer of pure polyglycolic acid (PGA) for the use in human cartilage tissue engineering under autologous conditions. Adult human chondrocytes were expanded in vitro using human serum and were rearranged three-dimensionally in human fibrin and PGA. The capacity of dedifferentiated chondrocytes to re-differentiate was evaluated after two weeks of tissue culture in vitro and after subcutaneous transplantation into nude mice by propidium iodide/fluorescein diacetate (PI/FDA) staining, scanning electron microscopy (SEM), gene expression analysis of typical chondrocyte marker genes and histological staining of proteoglycans and type II collagen. PI/FDA staining and SEM documented that vital human chondrocytes are evenly distributed within the polymer-based cartilage tissue engineering graft. The induction of the typical chondrocyte marker genes including cartilage oligomeric matrix protein (COMP) and cartilage link protein after two weeks of tissue culture indicates the initiation of chondrocyte re-differentiation by three-dimensional assembly in fibrin and PGA. Histological analysis of human cartilage tissue engineering grafts after 6 weeks of subcutaneous transplantation demonstrates the development of the graft towards hyaline cartilage with formation of a cartilaginous matrix comprising type II collagen and proteoglycan. These results suggest that human polymer-based cartilage tissue engineering grafts made of human chondrocytes, human fibrin and PGA are clinically suited for the regeneration of articular cartilage defects.
Endres
M
M
Charite-University Medicine Berlin, Department of Rheumatology, Tissue Engineering Laboratories, Berlin, Germany. michaela.endres@transtissue.com
Neumann
K
K
Schröder
S E A
SE
Vetterlein
S
S
Morawietz
L
L
Ringe
J
J
Sittinger
M
M
Kaps
C
C
D020341:Absorbable Implants / Q000592:standards*; D000368:Aged; D000818:Animals; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D002356:Cartilage / Q000166:cytology / Q000502:physiology / Q000637:transplantation*; D002358:Cartilage, Articular / Q000378:metabolism / Q000503:physiopathology*; D002454:Cell Differentiation / Q000502:physiology; D002478:Cells, Cultured; D019902:Chondrocytes / Q000166:cytology / Q000378:metabolism / Q000648:ultrastructure; D005337:Fibrin / Q000494:pharmacology; D006085:Graft Survival / Q000502:physiology; D048091:Guided Tissue Regeneration / Q000379:methods; D006801:Humans; D007592:Joint Diseases / Q000628:therapy; D051379:Mice; D008819:Mice, Nude; D008855:Microscopy, Electron, Scanning; D011100:Polyglycolic Acid / Q000627:therapeutic use*; D011108:Polymers / Q000627:therapeutic use; D012038:Regeneration / Q000502:physiology; D023822:Tissue Engineering / Q000379:methods*; D016378:Tissue Transplantation / Q000379:methods*; D014183:Transplantation, Heterologous / Q000379:methods
D015415:Biomarkers; D011108:Polymers; D011100:Polyglycolic Acid; D005337:Fibrin